Abstract: The present invention provides materials and methods for determining optimal dosage regimens for therapeutic agents. In particular, the invention relates to dosage regimens for therapeutic agents capable of targeting IL-2 receptor, preferably interleukin 2 (IL2)-based therapeutic agents. The methods of the invention allow general dosage regimens to be determined for new IL-2R targeted therapeutic agents but also specifically tailored dosage regimens to be achieved for individuals being treated with IL-2R targeted therapeutic agents.

Abstract: A dosage of an active ingredient in a treatment that is being provided to or that is being considered for provision to a subject is identified. A level of local amyloid beta is predicted based on the dosage of the active ingredient. A severity of amyloid-related imaging abnormalities (ARIA) manifested as hyperintensities on T2-weighted fluid attenuated inversion recovery (FLAIR) images (ARIA-E) is predicted based on the predicted removal of local amyloid beta, where predicting severity of ARIA-E includes predicting an extent of vascular wall disturbance. A result corresponding to the predicted ARIA-E severity is output.

Abstract: The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.

Abstract: The present invention provides materials and methods for determining optimal dosage regimens for therapeutic agents. In particular, the invention relates to dosage regimens for therapeutic agents capable of targeting IL-2 receptor, preferably interleukin 2 (IL2)-based therapeutic agents. The methods of the invention allow general dosage regimens to be determined for new IL-2R targeted therapeutic agents but also specifically tailored dosage regimens to be achieved for individuals being treated with IL-2R targeted therapeutic agents.

Abstract: The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.

Abstract: Bioresorbable pin systems useful for the reduction of bone fragments and for fixing bioresorbable membranes to a bone are provided, particularly pins having a detachable handle and a pre-fabricated hole in the handle through which a tether may be threaded to facilitate removal of the handle once it has been detached from the pin.